Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Peters

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Nature|May 20, 2005
Obituary: Saunders Mac Lane (1909-2005)Klaus Peters
Contraception|February 24, 2020
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phaseDan Apter, Enrico Colli, Kristina Gemzell-Danielsson, et al.
Climacteric : the Journal of the International Menopause Society|July 22, 2024
Use of an estradiol transdermal spray in women with menopausal symptoms: a non-interventional studyPeyman Hadji, Jens-Olaf Schmeißer, Klaus Peters, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|January 1, 2013
A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosisGilbert G G Donders, Secondo Guaschino, Klaus Peters, et al.
Deutsches Arzteblatt International|April 6, 2017
Mental Disorders in People Affected by ThalidomideAlexander Niecke, Klaus Peters, Christina Samel, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2012
Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiotaFederica Cruciani, Patrizia Brigidi, Fiorella Calanni, et al.
Human Vaccines & Immunotherapeutics|July 16, 2015
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized studyBarbara Romanowski, Tino F Schwarz, Linda Ferguson, et al.
Geburtshilfe Und Frauenheilkunde|December 13, 2022
Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Human Vaccines|November 4, 2011
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized studyBarbara Romanowski, Tino F Schwarz, Linda M Ferguson, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2021
Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Nature|May 20, 2005
Obituary: Saunders Mac Lane (1909-2005)Klaus Peters
Contraception|February 24, 2020
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phaseDan Apter, Enrico Colli, Kristina Gemzell-Danielsson, et al.
Climacteric : the Journal of the International Menopause Society|July 22, 2024
Use of an estradiol transdermal spray in women with menopausal symptoms: a non-interventional studyPeyman Hadji, Jens-Olaf Schmeißer, Klaus Peters, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|January 1, 2013
A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosisGilbert G G Donders, Secondo Guaschino, Klaus Peters, et al.
Deutsches Arzteblatt International|April 6, 2017
Mental Disorders in People Affected by ThalidomideAlexander Niecke, Klaus Peters, Christina Samel, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2012
Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiotaFederica Cruciani, Patrizia Brigidi, Fiorella Calanni, et al.
Human Vaccines & Immunotherapeutics|July 16, 2015
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized studyBarbara Romanowski, Tino F Schwarz, Linda Ferguson, et al.
Geburtshilfe Und Frauenheilkunde|December 13, 2022
Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Human Vaccines|November 4, 2011
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized studyBarbara Romanowski, Tino F Schwarz, Linda M Ferguson, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2021
Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Pageof 3